Back to SUPN overview
#
SUPN Supernus Pharmaceuticals
PE ratio, current and historical analysis

## SUPN PE ratio history

### Supernus Pharmaceuticals PE ratio by year

## SUPN average PE ratio chart

## SUPN PE vs peers

## Frequently asked questions

###
What is Supernus Pharmaceuticals's PE ratio?

###
What is the 3-year average PE ratio for Supernus Pharmaceuticals (SUPN)?

###
What is the 5-year average PE ratio for Supernus Pharmaceuticals (SUPN)?

###
What is the highest PE ratio for SUPN?

###
How does the current PE ratio for SUPN compare to its historical average?

###
How is SUPN's PE ratio calculated (Supernus Pharmaceuticals PE ratio formula)?

The current P/E ratio for Supernus Pharmaceuticals stock as of Feb 23, 2024 is 61.83. This is calculated based on the TTM EPS of $0.47 and the stock price of $29.06 per share. The PE ratio has increased by 49% from its last 4 quarters average of 41.5.

How has SUPN's PE ratio performed in the past

The average historical PE ratio of Supernus Pharmaceuticals for the last nine years is 32.2. The current price-to-earnings ratio of 61.83 is 92% more than the historical average. Analyzing the last nine years, SUPN's PE ratio reached its highest point in the Jun 2015 quarter at 169.8, when the price was $16.98 and the EPS was $0.1. The lowest point was recorded in the Mar 2020 quarter, when it reached 8.14 with a price of $17.99 and an EPS of $2.21.

Average

32.2

Median

26.36

Minimum

8.14

Maximum

169.8

Maximum annual increase: 176.53% in 2021

Maximum annual decrease: -70.39% in 2016

Year | PE ratio | Change |
---|---|---|

2022 | 31.57 | 9.35% |

2021 | 28.87 | 176.53% |

2020 | 10.44 | -4.92% |

2019 | 10.98 | -29.62% |

2018 | 15.6 | -55.77% |

2017 | 35.27 | 157.07% |

2016 | 13.72 | -70.39% |

2015 | 46.34 | N/A |

2014 | N/A | N/A |

2013 | N/A | N/A |

What is the average PE ratio of SUPN for the past years

The current PE ratio of SUPN is above its 3, 5 and 10-year averages.

3-year avg

30.74

5-year avg

22.88

10-year avg

32.2

15-year avg

N/A

What is SUPN's PE ratio compared to its peers

SUPN's PE ratio is less than its peer stock LLY, but it is above JNJ's and ABT's. Supernus Pharmaceuticals's current PE ratio of 61.83 is in line with the average of its peers, which is 18.05.

Stock name | PE ratio | Market cap |
---|---|---|

UTHR UNITED THERAPEUTICS Corp | 10.56 | $10.46B |

JNJ Johnson & Johnson | 11.58 | $387.06B |

BMY Bristol Myers Squibb Co | 13.11 | $102.85B |

ABT Abbott Laboratories | 36.12 | $205.59B |

SUPN Supernus Pharmaceuticals Inc | 62.94 | $1.62B |

LLY ELI LILLY & Co | 132.64 | $733.48B |

The price to earnings ratio for SUPN stock as of Feb 23, 2024, stands at 61.83.

Over the last 3 years, the average PE ratio for SUPN stock is 30.74.

Over the last 5 years, the average PE ratio for SUPN stock is 22.88.

The highest quarterly PE ratio in the last nine years has been 169.8 and it was in the Jun 2015 quarter.

The current PE ratio of SUPN is 92% higher than the 9-year historical average.

The P/E ratio is calculated by taking the latest stock price and dividing it by the earnings per share(EPS) for the last 12 months. As of today (Feb 23, 2024), Supernus Pharmaceuticals's share price is $29.06. The company's earnings per share for the trailing twelve months (TTM) ending Sep 2023 is $0.47. Therefore, Supernus Pharmaceuticals's price to earnings ratio for today is 61.83. `PE RATIO(61.83) = STOCK PRICE($29.06) / TTM EPS($0.47)`

All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.